Clinical data | |
---|---|
Trade names | Gidazepam IC |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | ~87 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H15BrN4O2 |
Molar mass | 387.237 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Gidazepam, also known as hydazepam or hidazepam,[2] is a drug which is an atypical benzodiazepine derivative, developed in the Soviet Union.[3][4] It is a selectively anxiolytic benzodiazepine.[5] It also has therapeutic value in the management of certain cardiovascular disorders.[6][7][8][9][10]
Gidazepam and several of its analogs, in contrast to other benzodiazepines, are comparatively more selective agonists of TSPO (formerly the peripheral benzodiazepine receptor) than the benzodiazepine receptor.[5]
Gidazepam acts as a prodrug to its active metabolite 7-bromo-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one (desalkylgidazepam or bromo-nordazepam).[11][12] Its anxiolytic effects can take several hours to manifest presumably due to the its slow metabolism (half-life 87 hours). The onset and intensity of anxiolytic effects correlate with blood levels of desalkylgidazepam.[13]
5-HT1AR agonists | |
---|---|
GABAAR PAMs |
|
Hypnotics | |
Gabapentinoids (α2δ VDCC blockers) | |
Antidepressants |
|
Antipsychotics | |
Sympatholytics (Antiadrenergics) |
|
Others | |
|